Gene sequence construct for gene therapy of human immunodeficiency virus infection
US-2024352096-A1 · Oct 24, 2024 · US
Novel hiv -1 broadly neutralizing antibodies
US2016289305A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016289305-A1 |
| Application number | US-201615132406-A |
| Country | US |
| Kind code | A1 |
| Filing date | Apr 19, 2016 |
| Priority date | Sep 24, 2010 |
| Publication date | Oct 6, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.
First claim
Opening claim text (preview).
1 - 13 . (canceled) 14 . An isolated or non-naturally occurring VRC-PG-05 monoclonal antibody comprising a heavy chain sequence of SEQ ID NO: 8 and a light chain sequence of SEQ ID NO: 16. 15 . A vector containing and expressing a nucleic acid encoding the VRC-PG-05 monoclonal antibody of claim 14 . 16 . A diagnostic composition comprising a labeled antibody of claim 14 or a fragment thereof, to detect the presence of an HIV immunogen, antigen or epitope in a sample. 17 . The composition of claim 16 , wherein the sample is a biological sample. 18 . The composition of claim 17 , wherein the biological sample is blood, semen or vaginal fluid.
Assignees
Inventors
Classifications
comprising antibodies · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title
for HIV · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016289305A1 cover?
- The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.
- Who is the assignee on this patent?
- Int Aids Vaccine Initiative, Scripps Research Inst, Us Health
- What technology area does this patent fall under?
- Primary CPC classification C07K16/1145. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Oct 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).